Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias

References

• Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804–815.
   PubMed Web of Science ®Google Scholar
• Croci DO, Zakaria FM, Rico MJ, . Dynamic cross talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 2007;56:1687–1700.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Wing K, Miyara M. Regulatory T cells – a brief history and perspective,Eur J Immunol 2007;37:S116–S123.
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Darabi K, . Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005;106:2018–2025.
   PubMed Web of Science ®Google Scholar
• Giannopoulos K, Schmitt M, Kowal M, . Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008;20:677–682.
   PubMed Web of Science ®Google Scholar
• Deutsch V, Perry C, Polliack A. Expansion of regulatory T cells in B cell CLL. Enhanced brakes on host immunity. Leuk Lymphoma 2009;50:788–801.
   PubMed Web of Science ®Google Scholar
• Biancotto A, Fuchs JC, Dagur P, . Characterization of Treg subpopulations in CLL using 15 color flow cytometry. Blood 2009;114(Suppl. 1): Abstract 1644.
   Google Scholar
• D’Arena G, Laurenti L, Minervini M, . Regulatory T cell number is increased in CLL patients and correlates with progressive disease. Leuk Res 2011;35:363–368.
   PubMed Web of Science ®Google Scholar
• Beyer M, Schultze J. Regulatory T cells in cancer. Blood 2006;108:804–11.
   PubMed Web of Science ®Google Scholar
• Lindquist CA, Christiansson LH, Mangsbo S, . FOXP3 T-cells in patients with B-cell CLL express cytolytic markers and kill autologous B cells. Immunology 2011;133:296–306.
   PubMed Web of Science ®Google Scholar
• Zhao DM, Thornton AM, DiPaolo RJ, . Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 2006;107:3925–3932.
   PubMed Web of Science ®Google Scholar
• Alvaro T, Lejeune M, Esciva P, . Appraisal of immune response in lymphoproliferative syndromes: a systematic review. Crit Rev Oncol Hematol 2009;70:103–113.
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Hafler DA. Human regulatory T cells and their role in autoimmune disease. Immunol Rev 2006;212:203–216.
   PubMed Web of Science ®Google Scholar
• Vila J, Isaacs JD, Anderson AE. Regulatory T cells and autoimmunity. Curr Opin Hematol 2009;16:274–279.
   PubMed Web of Science ®Google Scholar
• La Cava A. Tregs are regulated by cytokines: implications for autoimmunity. Autoimmun Rev 2008;8:83–87.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330–336.
   PubMed Web of Science ®Google Scholar
• Varma S, Lad D, Varma N, . Do regulatory T cells have a role in disease progression and autoimmune cytopenias of chronic lymphocytic leukemia?Blood 2011;118(Suppl. 1):Abstract 3864.
   Google Scholar
• Liu W, Putnam AL, Xu-Yu Z, . CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006;203:1701–1711.
   PubMed Web of Science ®Google Scholar
• Jak M, Mous R, Remmerswaal EB, . Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:788–801.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Shevach EM. Mechanisms of Foxp3 Treg cell mediated suppression. Immunity 2009;30:636–645.
   PubMed Web of Science ®Google Scholar
• Waldmann H, Cobbold S. Regulatory T cells: context matters. Immunity 2009;5:613–615.
   Web of Science ®Google Scholar
• Molica S, Alberti A. Prognostic value of lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987;60:2712–2716.
   PubMed Web of Science ®Google Scholar
• Zent CS, Ding W, Reinalda MS, . Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma 2009;50:1261–1268.
   PubMed Web of Science ®Google Scholar
• Awasthi A, Murugaiyan G, Kuchroo VK. Interplay between effector Th17 and regulatory T cells. J Clin Immunol 2008;28:660–670.
   PubMed Web of Science ®Google Scholar
• Marti G, Orfao A, Goolsby C. ZAP-70 in CLL: towards standardization of a biomarker for patient management: history of clinical cytometry special issue. Cytometry B Clin Cytom 2006;70:197–200.
   PubMed Web of Science ®Google Scholar
• Weiss L, Melchardt T, Egle A, . Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 2011;117:2163–2169.
   PubMed Web of Science ®Google Scholar
• Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 2007;7:880–887.
   PubMed Web of Science ®Google Scholar